MX374290B - Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. - Google Patents

Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.

Info

Publication number
MX374290B
MX374290B MX2016005801A MX2016005801A MX374290B MX 374290 B MX374290 B MX 374290B MX 2016005801 A MX2016005801 A MX 2016005801A MX 2016005801 A MX2016005801 A MX 2016005801A MX 374290 B MX374290 B MX 374290B
Authority
MX
Mexico
Prior art keywords
antibody
btk inhibitor
cancer
treatment
combination
Prior art date
Application number
MX2016005801A
Other languages
English (en)
Other versions
MX2016005801A (es
Inventor
Christian Klein
Yasuhiro Tomoko
Yoshizawa Toshio
Original Assignee
Ono Pharmaceutical Co
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Hoffmann La Roche filed Critical Ono Pharmaceutical Co
Publication of MX2016005801A publication Critical patent/MX2016005801A/es
Publication of MX374290B publication Critical patent/MX374290B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 con un inhibidor de BTK para el tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de BTK.
MX2016005801A 2013-11-07 2014-11-04 Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer. MX374290B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07
PCT/EP2014/073640 WO2015067586A2 (en) 2013-11-07 2014-11-04 Combination therapy of an anti cd20 antibody with a btk inhibitor

Publications (2)

Publication Number Publication Date
MX2016005801A MX2016005801A (es) 2016-11-29
MX374290B true MX374290B (es) 2025-03-06

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005801A MX374290B (es) 2013-11-07 2014-11-04 Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.

Country Status (20)

Country Link
US (3) US20150125446A1 (es)
EP (1) EP3066126B1 (es)
JP (1) JP6478989B2 (es)
KR (1) KR101874215B1 (es)
CN (3) CN113995843A (es)
AR (1) AR098328A1 (es)
AU (1) AU2014345712B2 (es)
CA (1) CA2926893C (es)
ES (1) ES2728350T3 (es)
HK (1) HK1222803A1 (es)
IL (1) IL244960B (es)
MX (1) MX374290B (es)
MY (1) MY178726A (es)
NZ (1) NZ718792A (es)
PH (1) PH12016500839A1 (es)
PL (1) PL3066126T3 (es)
RU (1) RU2727650C2 (es)
TR (1) TR201907240T4 (es)
TW (1) TWI524899B (es)
WO (1) WO2015067586A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
BR112014012727B1 (pt) 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
WO2015146159A1 (en) * 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
CA2979671C (en) * 2014-09-23 2020-03-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
JP6750613B2 (ja) 2015-04-09 2020-09-02 小野薬品工業株式会社 プリノン誘導体の製造方法
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AU2016304172A1 (en) * 2015-08-03 2018-03-15 Gilead Sciences, Inc. Combination therapies for treating cancers
JP6890581B2 (ja) 2015-08-28 2021-06-18 デビオファーム インターナショナル, エス. アー. Cd37の検出のための抗体およびアッセイ
ES2900482T3 (es) * 2015-10-01 2022-03-17 Gilead Sciences Inc Combinación de un inhibidor de Btk y un inhibidor de punto de control para el tratamiento del cáncer
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
EP3355871A1 (en) * 2015-10-02 2018-08-08 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
AU2018314765C1 (en) 2017-08-08 2025-11-20 Bruker Spatial Biology, Inc. Obinutuzumab treatment of a DLBCL patient subgroup
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
WO2021170045A1 (en) * 2020-02-27 2021-09-02 Beigene Switzerland Gmbh Methods of treating dlbcl using btk inhibitors and combinations thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Cd20에 대한 인간 모노클로날 항체
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
JP5588865B2 (ja) * 2007-07-31 2014-09-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトcd20に対するヒト抗体及びその使用方法
US8940725B2 (en) * 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
US20140303191A1 (en) * 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
BR112014012727B1 (pt) * 2011-11-29 2022-10-25 Ono Pharmaceutical Co., Ltd Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica
WO2014081712A2 (en) * 2012-11-20 2014-05-30 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with bruton's tyrosine kinase
KR20160013204A (ko) 2013-05-30 2016-02-03 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료
EP3076974A1 (en) 2013-12-05 2016-10-12 Acerta Pharma B.V. Therapeutic combination of a pi3k inhibitor and a btk inhibitor
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
RS63364B1 (sr) 2014-08-11 2022-07-29 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora

Also Published As

Publication number Publication date
CN105792846A (zh) 2016-07-20
AU2014345712B2 (en) 2019-10-17
CN113995843A (zh) 2022-02-01
KR101874215B1 (ko) 2018-07-03
AR098328A1 (es) 2016-05-26
JP6478989B2 (ja) 2019-03-06
CA2926893C (en) 2022-04-12
WO2015067586A2 (en) 2015-05-14
MY178726A (en) 2020-10-20
TW201521767A (zh) 2015-06-16
JP2016536298A (ja) 2016-11-24
US12186392B2 (en) 2025-01-07
EP3066126A2 (en) 2016-09-14
HK1222803A1 (zh) 2017-07-14
WO2015067586A3 (en) 2015-07-30
MX2016005801A (es) 2016-11-29
US20250205333A1 (en) 2025-06-26
PL3066126T3 (pl) 2019-08-30
RU2727650C2 (ru) 2020-07-22
ES2728350T3 (es) 2019-10-23
TR201907240T4 (tr) 2019-06-21
IL244960A0 (en) 2016-05-31
AU2014345712A1 (en) 2016-05-05
CA2926893A1 (en) 2015-05-14
NZ718792A (en) 2020-05-29
PH12016500839A1 (en) 2016-06-13
US20150125446A1 (en) 2015-05-07
US20200171153A1 (en) 2020-06-04
RU2016122232A (ru) 2017-12-08
KR20160079869A (ko) 2016-07-06
EP3066126B1 (en) 2019-03-27
IL244960B (en) 2021-08-31
TWI524899B (zh) 2016-03-11
BR112016010271A2 (pt) 2017-10-03
CN114632158A (zh) 2022-06-17
RU2016122232A3 (es) 2018-06-18

Similar Documents

Publication Publication Date Title
NZ718792A (en) Combination therapy of an anti cd20 antibody with a btk inhibitor
MX389342B (es) Un anticuerpo anti-cd20 en combinación con un inhibidor de bcl-2 y un inhibidor de mdm2 para usarse en el tratamiento de cáncer.
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX378546B (es) Combinaciones con anticuerpos anti-cd38 para usarse en el tratamiento de un sujeto que tiene una neoplasia maligna hematológica cd38-positivo
GEP20217331B (en) Anti-tigit antibodies
CO2017001191A2 (es) Conjugados de fármacos con anticuerpos anti-cdh6
HUE065528T2 (hu) Zanubrutinib kombinációja anti-CD20 vagy anti-PD-1 antitesttel rák kezelésében történõ alkalmazásra
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
PL2958945T3 (pl) Terapia skojarzona wykorzystująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu
TN2015000396A1 (en) Antibody drug conjugates
CL2016001586A1 (es) Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40
MX370597B (es) Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer.
MX2017005553A (es) Terapia de combinacion para cancer.
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
MX2016002974A (es) Eteres de arilo y sus usos.
PT2976360T (pt) Terapia envolvendo anticorpos contra claudina 18.2 para o tratamento de cancro
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
MX2015014501A (es) Terapia de combinacion de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd22-farmaco.
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
CR20170537A (es) Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.
EA201591304A1 (ru) Применение комплекса, облегчающего транскрипцию хроматина (fact), при раке

Legal Events

Date Code Title Description
FG Grant or registration